- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adam Simmons Explains the Importance of Finding New Treatment Options for Schizophrenia
Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.
Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine.
Transcript
Can you discuss the importance of finding new treatment options for people with schizophrenia?
Although there’s been a number of treatments and new therapies that have been developed since olanzapine’s come to the market, we still know that olanzapine is still one of the most effective antipsychotics, that it’s one of the most commonly used. And that being despite the fact that olanzapine has this propensity for causing large, clinically significant amounts of weight gain.
So the objective here, and what it is that we’ve tried to do with our development program, is demonstrate that we still have that same efficacy of olanzapine that has been established and is very well supported in the literature, but reducing some of that weight gain. And the benefits there, of course, are that we know that weight gain is associated with, as you mentioned, cardiovascular disease, diabetes, as well as the social reasons and stigma that goes along with increased amounts of weight gain.
So for people that need the efficacy of olanzapine but without that additional weight gain and all the disadvantages that go along with that, that’s where we think that 3831 offers a benefit for patients.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
